We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+5.18%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.58B
AUM Growth
+$79.4M
Cap. Flow
-$357M
Cap. Flow %
-3.72%
Top 10 Hldgs %
37.69%
Holding
157
New
16
Increased
39
Reduced
32
Closed
21

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$158M
2
MOH icon
Molina Healthcare
MOH
+$98.2M
3
MRK icon
Merck
MRK
+$95.1M
4
ZBH icon
Zimmer Biomet
ZBH
+$88.5M
5
MDVN
MEDIVATION, INC.
MDVN
+$85.1M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$182M
2
CELG
Celgene Corp
CELG
+$142M
3
HCA icon
HCA Healthcare
HCA
+$129M
4
AGN.PRA
Allergan plc
AGN.PRA
+$87M
5
TSRO
TESARO, Inc.
TSRO
+$84.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Miscellaneous 5.91%
3 Financials 0.34%
4 Technology 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
26
DELISTED
MEDIVATION, INC.
MDVN
$121M 1.26%
2,001,400
+1,500,400
+299% +$85.1M
ILMN icon
27
Illumina
ILMN
$32.6B
$119M 1.24%
869,894
-55,306
-6% -$7.86M
BMRN icon
28
BioMarin Pharmaceuticals
BMRN
$12.5B
$118M 1.23%
1,518,500
+495,300
+48% +$42.1M
LLY icon
29
Eli Lilly
LLY
$1.02T
$116M 1.21%
1,476,800
-1,064,500
-42% -$80.1M
COO icon
30
Cooper Companies
COO
$10.3B
$116M 1.21%
2,705,200
-478,400
-15% -$19.1M
WMGI
31
DELISTED
Wright Medical Group Inc
WMGI
$114M 1.19%
6,545,163
-1,799,947
-22% -$33M
MRK icon
32
Merck
MRK
$354B
$110M 1.15%
2,007,444
+1,786,945
+810% +$95.1M
ISEE
33
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$110M 1.14%
2,148,100
+53,600
+3% +$2.66M
ZBH icon
34
Zimmer Biomet
ZBH
$18.6B
$104M 1.08%
888,375
+782,285
+737% +$88.5M
JNJ icon
35
Johnson & Johnson
JNJ
$636B
$94.3M 0.98%
777,600
+245,800
+46% +$27.9M
MOH icon
36
Molina Healthcare
MOH
$10.9B
$91.7M 0.96%
+1,838,000
New +$98.2M
ACHN
37
DELISTED
Achillion Pharmaceuticals
ACHN
$91.1M 0.95%
11,681,600
+161,900
+1% +$1.39M
PBYI icon
38
Puma Biotechnology
PBYI
$476M
$88.3M 0.92%
2,964,025
+210,600
+8% +$6.58M
AGN.PRA
39
DELISTED
Allergan plc
AGN.PRA
– –
-104,200
Closed -$87M
GKOS icon
40
Glaukos
GKOS
$10B
$84.5M 0.88%
2,897,938
– –
NBIX icon
41
Neurocrine Biosciences
NBIX
$15.5B
$82.5M 0.86%
1,815,474
-838,400
-32% -$38.6M
MNK
42
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$79.6M 0.83%
1,309,000
– –
CRVS icon
43
Corvus Pharmaceuticals
CRVS
$1.06B
$76.7M 0.8%
5,379,349
+120,899
+2% +$1.63M
SHPG
44
DELISTED
Shire pic
SHPG
$72.5M 0.76%
394,009
+93,638
+31% +$16.9M
MGLN
45
DELISTED
Magellan Health Services, Inc.
MGLN
$71.7M 0.75%
1,090,600
-818,400
-43% -$55.1M
HUM icon
46
Humana
HUM
$47.7B
$61.1M 0.64%
339,700
– –
INSY
47
DELISTED
Insys Therapeutics, Inc.
INSY
$60.7M 0.63%
4,688,240
+130,500
+3% +$1.9M
MDT icon
48
Medtronic
MDT
$119B
$57.8M 0.6%
666,299
– –
NTLA icon
49
Intellia Therapeutics
NTLA
$1.59B
$56.8M 0.59%
+2,662,180
New +$70.8M
BLUE
50
DELISTED
bluebird bio
BLUE
$51.3M 0.54%
91,544
+18,551
+25% +$10.5M
1
2
3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2016 Portfolio in Review

As of Q2 2016, OrbiMed held 157 positions worth $9.58B, up 0.84% from $9.5B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed withdrew a net $357M in Q2 2016, closing 21 positions and reducing 32 holdings. Its most notable exit was Allergan plc, an estimated $87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, OrbiMed opened a new position in Molina Healthcare worth $91.7M.

  • OrbiMed's largest Q2 2016 buy was Molina Healthcare: 1,838,000 shares worth $91.7M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q2 2016, an estimated $158M increase.
  • OrbiMed's biggest Q2 2016 reduction was Bristol-Myers Squibb, cutting an estimated $182M.
  • OrbiMed fully exited Allergan plc in Q2 2016, selling an estimated $87M.
  • OrbiMed's ten largest holdings make up 38% of its $9.58B portfolio in Q2 2016.
  • OrbiMed opened 16 new positions and closed 21 in Q2 2016.
  • OrbiMed's portfolio value rose 0.84% quarter-over-quarter to $9.58B.

Based on OrbiMed's 13F filing for Q2 2016, filed 15 Aug 2016.